Chronic obstructive pulmonary disease (COPD) is a chronic disease that results in obstructed airflow to the lungs, causing symptoms including breathlessness, frequent coughing, wheezing, and chest tightness. The disease can be caused by the inhalation of pollutants including smoke and second-hand smoke, fumes, chemicals, and dust. Genetic factors can also play a role in the development of COPD, regardless of exposure to irritants.
COPD includes progressive lung diseases such as chronic bronchitis and may develop for years without noticeable symptoms until later stages of the disease. Because of this, it is estimated that COPD affects over 30 million individuals in the United States, more than half of whom are undiagnosed.
Individuals with COPD are more likely to develop respiratory infections including pneumonia, and there is no cure for COPD. Current treatment options including bronchodilators and steroids can have serious side effects such as headaches, heart palpitations, weight gain, osteoporosis, and increased risk of infection.
Synspira is developing the proprietary modified polysaccharide molecule SNSP146 for the treatment of chronic bronchitis and exacerbations in COPD. SNSP146 interacts at the pulmonary surface to reduce inflammation and prevent pulmonary exacerbations.